U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday.